These results are consistent with the published study suggesting that metformin is therapeutically more effective in T2DM patients with GG genotype of SLC47A1. 11,20 The association of genotypic variants with response of metformin revealed that Pakistani carriers of minor allele (A) were more likely to be non-responders and exhibit unsatisfactory glycemic control. Here, SLC47A1 is linked to type 2 diabetes mellitus.